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Abstract 
Complementary DNA clones corresponding to a messenger RNA encoding a 56 kDa polypeptide have been obtained from Torpedo marmorata 
and Torpedo ocellata electric lobe libraries, by homology screening with a probe obtained from the putative acetylcholine transporter from the 
nematode Caenorhabditis elegant. The Torpedo proteins display approximately 50% overall identity to the C. elegans am-1 7 protein and 43% identity 
to the two vesicle monoamine transporters (VMATl and VMAT2). This family of proteins is highly conserved within 12 domains which potentially 
span the vesicle membrane, with little similarity within the putative i&alumina1 glycosylated loop and at the N- and C-termini. The _ 3.0 kb mRNA 
species is specifically expressed in the brain and highly enriched in the electric lobe of Torpedo. The Torpedo protein, expressed in CV-1 fibroblast 
cells, possesses a high-affinity binding site for vesamicol (& = 6 nM), a drug which blocks in vitro and in vivo acetylcholine accumulation in 
choline@ vesicles. 
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1. Introduction 
Acetylcholine is an excitatory neurotransmitter at the 
skeletal neuromuscular junction, within the autonomic 
nervous system, and in the brain of vertebrates. In 
cholinergic nerve endings, acetylcholine is stored and 
concentrated in the synaptic vesicles [l-3]. The charac- 
teristics of acetylcholine transport have been well studied 
in isolated synaptic vesicles which can be prepared in 
high yield and purity from the electric organ of the ma- 
rine ray Torpedo [l+lO]. Acetylcholine transport and 
storage in this preparation depends on a transmembrane 
proton-electrochemical gradient maintained by an elec- 
trogenic vacuolar-type H’-ATPase [9-121. ChromafEn 
vesicle accumulation of biogenic amines has also been 
shown to depend on this gradient [ 131. Thus, a common 
*Corresponding author. Fax: (33) (1) 69 82 94 66. 
bioenergetic mechanism exists for accumulation of the 
positively charged neurotransmitters acetylcholine and 
biogenic amines in acidic intracellular organelles by pro- 
ton exchange [14,151. 
Vesamicol (+)trans-2-(4-phenylpiperidino) cyclohex- 
anol (also known as AH5183) is a drug that blocks 
cholinergic neurotransmission by interfering with vesic- 
ular acetylcholine storage in vivo [16,17]. Its action in- 
volves inhibition of acetylcholine uptake into synaptic 
vesicles by binding to a single population of sites on the 
cholinergic vesicle [ 18,191. Pharmacological studies on 
the interaction of acetylcholine and vesamicol with Tor- 
pedo vesicles and vesicle membrane preparations uggest 
that the vesamicol binding site is within the acetylcholine 
vesicular transporter [19,20], although a single polypep- 
tide binding both vesamicol and acetylcholine has not yet 
been identified. 
cDNAs encoding the vesicle monoamine transporters 
VMATl and VMAT2 have been cloned and expressed 
in heterologous mammalian cells. This has allowed un- 
equivocal demonstration that high-affinity ATP-depend- 
ent uptake of biogenic amines and binding of specific 
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inhibitors to the transporter are reconstituted by expres- 
sion of a single polypeptide [21-251. 
Recently, the cDNA corresponding to the gene re- 
sponsible for the unc-17 uncoordinated phenotype of C. 
elegans was cloned and sequenced [26]. The unc-17 gene 
product (UNC-17) has been proposed as the vesicular 
acetylcholine transporter based on (i) its striking ho- 
mology to the mammalian vesicle monoamine trans- 
porters, (ii) its expression in cholinergic nerve endings, 
and (iii) the observed defects in cholinergic skeletal mus- 
cle neurotransmission i unc-mutants consistent with the 
absence of vesicular cholinergic transport [26]. 
In the present work, we attempted to identify the 
UNC-17 homolog from Torpedo, a species in which the 
pharmacology of the vesicular acetylcholine transporter 
has been sufficiently well characterized to allow defini- 
tive analysis of the binding properties of the protein in 
a heterologous ystem. 
2. Materials and methods 
2.1. Cloning 
A cDNA library from Torpedo marmorata electric lobe was con- 
structed in bacteriophage il vector (ZAP-cDNA synthesis kit, Strat- 
agene). 6 x 10’ plaques were plated, blotted onto duplicate nitrocellu- 
lose filters (Hybond N+; Amersham) and screened with a random 
primed (Nonaprimer I labeling kit; Stratagene) “P-labeled C. elegans 
unc-17 coding sequence (base 116 to 1,454; Genbank Accession No. 
L19621). Prehybridization (3 h) and hybridization (18 h; lo6 cpm/ml) 
were performed at 45°C in a buffer containing 6 x SSPE; 20% deionized 
formamide; 2 x Denhardt’s solution; 250 mg/ml herring sperm DNA 
(sheared and heat denatured). Non-specific hybridization was elimi- 
nated by three 15 min washes with 1 x SSPE; 0.1% SDS, at 45°C. 
Clones detected as positive through 3 successive platings were isolated 
as Bluescript II SK plasmids by in vivo excision with helper phage R408 
(Stratagene). 
A cDNA library was also constructed in a variation of the Okayama- 
Berg cDNA expression vector (pcdSP6/T7) from Torpedo ocellata (M.J. 
Brownstein, Laboratory of Cell Biology, NIMH). The library was sub- 
divided (48 pools of 7,500 recombinants) and Southern blots of BamHI 
restriction digests of plasmid prepared from overnight cultures were 
hybridized in a buffer containing 4 x SSC; 25% formamide; 5 x Den- 
hardt’s solution; 200 &ml tRNA, with a random-primed 32P-labeled 
C. elegans unc-17 coding sequence (base 206 to l,i91) at 45°C. The 
filters were washed in 3 x SSC: 0.1% SDS. at 60°C. Autoradiograuhs 
were analyzed using a BAS2000 phosphor-imaging system (Fiji’Bi- 
omedical, Stamford, CT) after 12 h exposure. Pools of recombinants 
expressing longer hybridizing clones were then plated to isolate a single 
cDNA clone. Sequence analysis revealed this cDNA to lack a portion 
of the 5’ end including 20 N-terminal amino acids. The 5’ region of this 
cDNA was obtained by using the polymerase chain reaction on plasmid 
from the total cDNA librarv with a sense mimer in the ncdSP6/T7 
vector (GCCAGTGAATGGGTTGGAAA) and an antisense primer in 
the coding sequence of YY ocellata (CCGTTGGAAGG- 
TATTGTGAT). This fragment (- 400 bp) was then digested with PstI 
which cuts in the vector and the cDNA portions of the PCR product, 
subcloned in pUC18 and sequenced. 
2.2. Sequencing 
The Torpedo marmorata cDNA was sequenced by using primers 
along both strands and Sequenase II according to the manufacturer 
instructions (USB, Amersham) and the Taq Dye Deoxy Terminator 
cycle sequencing kit (Applied Biosystems). 
The Torpedo ocellata cDNA was sequenced by subcloning overlap- 
ping fragments into pUC18. DNA was amplified directly from individ- 
ual colonies by PCR using primers flanking pUC18, purified on Magic 
PCR columns (Promega, Madison, WI), cycle sequenced using ABI dye 
primers, and analyzed on an ABI model 373A sequencer (Applied 
Biosystems, Inc., Foster City, CA). Sequence data were assembled 
using the Seqman program (DNASTAR, Madison, WI) and analyzed 
using DNA Strider [27]. Predicted transmembrane segments of the 
protein was estimated by hydropathy analysis [28]. 
2.3. Northern analysis 
Poly(A)’ RNA was purified by the guanidinium isothiocyanate/ 
cesium chloride method followed by oligo-dT cellulose chromatogra- 
phy [29]. Poly(A)’ RNA (6 pg per lane) was dissolved in 20 ~1 of a 
solution containing 2.2 M formaldehyde; 50% formamide; 20 mM 
MOPS; 5 mM sodium acetate; 1 mM EDTA (pH 7.0); 0.025% Bromo- 
phenol blue, and denatured at 60°C for 10 min. The RNA was electro- 
phoresed in 1 .O% agarose gels containing 2.2 M formaldehyde; 20 mM 
MOPS; 5 mM sodium acetate: 1 mM EDTA. After transfer to nitrocel- 
lulose membranes (Hybond d extra, Amersham) the RNA blots were 
baked at 80°C (3 h), prehybridized (3 h) and then hybridized with 
random primed “P-labeled Torpedo marmorata cDNA probe (1 O6 cpm/ 
ml) in a buffer containing 6 x SSPE; 50% formamide; 1 x Denhardt’s 
solution; 250 pg/ml salmon sperm DNA (sheared and heat denatured) 
for 18 h at 45°C. The filters were washed in 0.1 x SSC; 0.1% SDS at 
60°C and exposed to X-ray film with an intensifying screen at -70°C. 
2.4. In situ hybridization histochemistry 
Torpedo brains were removed and rapidly cut into coronal and sag- 
ittal pieces. The tissue was fixed overnight at room temperature in 100 
mM sodium-phosphate buffer (pH 7.4), 300 mM NaCl, 4% paraformal- 
dehyde and subsequently transferred to phosphate buffer containing 
20% sucrose for at least 24 h at 4°C. Tissue pieces were then frozen in 
chilled isopentane on dry ice and 10 pm sections were cut on a Leitz 
cryostat, mounted on gelatin coated slides and stored at -70°C until 
use. An oligodeoxynucleotide (45-mer; GAGCATGTTGTCCAATA- 
ACATTGCTATGCACACGATGACAAGCAG) complementary to 
the coding region of Torpedo marmorata was synthesized on an Applied 
Biosystems 380A DNA synthesizer and labeled to a specific activity of 
0.5-l x lo9 cpm/pg using terminal deoxynucleotidyl transferase 
(Boehringer) and [a-‘?j]dATP. Sections were also hybridized with the 
full length Torpedo marmorata cDNA labeled by random-priming using 
[a-“P]dATP. The sections were thawed at room temperature, fixed in 
2% paraformaldehyde; 150 mM phosphate buffer (pH 7.4), rinsed twice 
with phosphate buffer, dehydrated in ethanol solution and air-dried. 
After prehybridation (3 h) in buffer containing 6 x SSPE, 1 x Den- 
hardt’s solution; 250 pg/ml salmon sperm DNA (sheared and heat 
denatured), hybridization was performed in buffer containing 4 x SSC; 
50% formamide; 1 x Denhardt’s olution; 250 pg/ml tRNA; 500 &ml 
salmon sperm DNA; 10 mM dithiothreitol and labeled probe (lo6 
cpm/slide) for 16 h at 40°C in a humid chamber. Slides were washed 
in 0.1 x SSPE at 4O”C, air dried and exposed to Hyperfilm /?-max 
(Amersham) for 4 days at -70°C. 
2.5. Recombinant vaccinia virus infection and transfection of CV-I cells 
Functional expression of cDNA’s was performed using the vaccinia 
virus/bacteriophage T7 hybrid system [30,31] which enables high level 
expression of vesicle membrane proteins. The cDNA clones used were 
prepared as follows. The Torpedo marmorata (XhoI-NotI) and unc-17 
(EcoRV-XbaI) full-length inserts were subcloned into pcDNAI/Amp 
(Invitrogen). The human VMATl and VMATZ clones were obtained 
from a human pheochromocytoma cDNA library in pcdm71Amp 
(Erickson et al., unpublished). Monkey kidney fibroblasts (CV-1 cells) 
were cultured in Dulbecco’s modified Eagle medium containing 10% 
fetal bovine serum, penicillin (100 U/ml), streptomycin (100 mg/ml) and 
glutamine (4 mM). Cells were plated at 2 x lo6 per plate (10 cm) and 
infected the following day with-a recombinant vaccinia virus encoding 
bacteriophage T7 RNA polymerase at a multiplicity of infection of 10. 
After 30 min the cells were transfected with plasmid DNA (1 j&ml) by 
using Transfectace (10 &ml, Bethesda Research Laboratories). After 
16 h the cells were washed with phosphate-buffered saline, harvested 
and homogenized (Dounce, type B pestle) in buffer containing 0.1 M 
sucrose: 10 mM Tris (DH 7.41: 5 mM EDTA: 6 &ml leupentin; 10 
pg/ml iepstatin; 1 mM~henylmethanesulfonyl’flu&~de; 5 j&&l aprot- 
inin, at 4°C. The suspension was centrifuged at 3,000 rpm for 10 min 
and the supematant was centrifuged at 100,000 x g for 60 min. Mem- 
brane pellets were stored at -70°C until use. 
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2.6. rH] Vesamicol binding assay 
Vesamicol binding was performed as described previously with 
minor modifications [32]. Briefly, membranes were thawed, suspended 
at 0.5-l mg/ml and incubated under gentle shaking for 45 min at room 
temperature in the presence of 50 mM sodi~-phosp~te buffer @H 
7.4), 2 mM chaps and unlabeled vesamicol (Research I&chemicals 
Incorporated) or vehicle, and various concentrations of t$H]vesamicol 
(49 Cilmmol, New England Nuclear). Bound [‘Hlvesamicol was meas- 
ured by vacuum filtration on glass fiber filters. Non-specific binding in 
the presence of 30pM of unlabeled ligand was subtracted from the total 
binding. protein concentration was determined by the method of Lowry 
[33] in the presence of 1% SDS, with bovine serum albumin as a 
standard. 
3. Results 
3.1. Sequence analysis of the Torpedo cDNAs 
Torpedo ~rmorata and oeel~ata cDNA libraries were 
screened under reduced stringency with a probe derived 
from the coding sequence of Caenorhabditis elegans unc- 
17. The nucleic acid sequence of the ocellata cDNA 
(Genbank Accession no. U05339) predicts an open 
reading frame of 1,533 base pairs using as the initiation 
codon the first ATG after an in-frame termination 
codon. The initiation codon in the marmorata cDNA 
sequence (Genbank Accession No. UO5591) is not as 
99 
clearly defined and has been taken to be the ATG ho- 
mologous to the ocellata initiation codon. This choice of 
initiation codon is consistent with the position of the 
initiation codon in a homologous rat cDNA (unpub- 
lished data). The predicted Torpedo proteins are both 
5 11 amino acids with a molecular mass of approximately 
56 kDa. The ammo acid conservation between Torpedo 
species is 98%. The Torpedo proteins are 50% identical 
to UNC-17 and 43% identical to the rat vesicle mono- 
amine transposes VMATl and VMAT2. Hydrophobic- 
ity analysis predicted 12 transmembrane domains (TM 
1-12). The highest sequence conservation between this 
family of proteins occurs within these assigned TM do- 
mains. TM domains 1, 4, 5 and 11 display the highest 
conservation between Torpedo and C. elegans with ap- 
proximately 90% identity. Torpedo and C. eIegans pro- 
teins are more similar to each other in TM domains 4 and 
5 than they are to VMATs. TM domains 1, 2 and 11 of 
Torpedo are approximately 65% identical with VMATs. 
The greatest divergence between the sequences of Tor- 
pedo, UNC-17 and the two forms of VMAT occurs in 
the large luminal loop located between the first two 
transmembrane domains and in the cytoplasmic N- and 
C-termini of these proteins (< 10% identity). Three po- 
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Fig. 1. Predicted amino acid sequence (single-letter code) of the Torpedo tnarmorata and oceliata proteins. (*) positions where the UNC-17 and the 
rat vesicle monoamine transporters VMATl and VMAT2 are identical to the Torpedo marmorata sequence. Gaps (-) are introduced to maximize 
alignment. Putative transmembrane domains (TM) 1-12 are boxed. (u) potential N-linked glycosylation sites. (0) Potential protein kinase C 
phospho~lation sites. 
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Fig. 2. Northern hybridization analysis of mRNA (6,~g) from different 
tissues of Torpedo marmorata: Lane 1, kidney; 2, liver; 3, electric organ; 
4 and 5, electric lobe. Lanes 4 and 5 are different samples of RNA which 
underwent one or two cycles of purification on oligo dT-cellulose resin. 
Blots were washed under stringent conditions and a - 3 kb mRNA 
transcript was detected only in the electric lobe. Exposure time was 
approximately 4 days at -70°C with an intensifying screen. 
tential sites for N-linked glycosylation for the Torpedo 
proteins are located within this luminal loop and one 
exists between TM domains 7 and 8. Three potential sites 
for phosphorylation by protein kinase C are located on 
the cytoplasmic face of the Torpedo proteins. 
Telencephalon 
Diencephalon 
.- 
Within the assigned TM domains of the Torpedo pro- 
teins are located several charged amino acid residues. An 
aspartic acid residue is found in TM domains 1,4, 6, 10 
and 11 and a lysine residue is located in TM domain 2. 
Aspartic acids in TM 1, 6, 10 and 11 and lysine in TM 
domain 2 are conserved between these proteins, UNC- 17 
and both VMATl and VMAT2. The Torpedo and C. 
elegans proteins contain an additional aspartic acid resi- 
due in TM domain 4 which is not found in VMATs. 
3.2. Tissue-spec$c mRNA expression 
A - 3.0 kb mRNA species was identified in poly(A)’ 
RNA from the electric lobe of Torpedo brain by North- 
ern blot analysis (Fig. 2). Hybridization to the Torpedo 
cDNA was not observed in the electric organ, liver, or 
kidney. In situ hybridization histochemistry of Torpedo 
brain sections clearly showed intense labeling of the elec- 
tric lobe (Fig. 3). 
3.3. [‘H] Vesamicol binding 
L-[3H]vesamicol binding to membranes of Torpedo 
marmorata, C. elegans unc-I 7, human VMATl or 
VMAT2 transfected cells is shown in Fig. 4. Analysis of 
binding revealed affinity constants (K,) of 6.4 + 0.4 nM 
for Torpedo and 124.2 f 7.9 nM for UNC-17. The spe- 
cific binding was not different in membranes prepared 
from mock transfected cells (455.1 + 75.2 nM) (data not 
shown) and those from VMATl or VMAT2 
(430.1 f 97.7 nM) expressing cells. While the infection 
and transfection efficiency of these experiments were not 
measured the apparent difference in the number of bind- 
ing site between Torpedo and C. elegans may correspond 
to the efficiency of transfection, protein stability, or pos- 
sibly the expression in different membrane compart- 
ments. 
Electric lobe A 
. . . . . . . . . . . 
Rhombencephalon 
Fig. 3. Representative autoradiograms of in situ hybridization in the brain of Torpedo marmorata. (A) Coronal sections hybridized with an ‘5S-labeled 
45-mer oligonucleotide probe. Sagittal sections were hybridized with a 33P-labeled cDNA probe and included telencephalon (B); mesencephalon (C); 
electric lobe and rhombencephalon (D); and (E) enlarged view of labeled electroneurons on a sagittal section. Levels are indicated on panel A. 
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Fig. 4. t$H]Vesamicol binding to membranes of Torpedo marmorata, C. elegans unc-17, human VMATl or VMATZ transfected fibroblasts. Specific 
binding was measured as described in section 2. Data are the mean of duplicate determinations and the experiments were repeated once with similar 
results. l , VMATl; CI, VMATZ. 
4. Discussion 
The electric lobe of the Torpedo abundantly expresses 
a messenger RNA encoding a protein with a high degree 
of homology to UNC-17, the putative vesicular ace- 
tylcholine transporter from C. elegum which was used to 
obtain the Torpedo cDNA by low-stringency screening 
of two Torpedo electric lobe cDNA libraries. This pro- 
tein and UNC-17 possess significant homology to 
VMATl and VMAT2, mammalian proteins that medi- 
ate biogenic amine transport into acidic intracellular or- 
ganelles via a proton electrochemical gradient. Sequence 
homology between members of this family exhibits 
strongest conservation within the transmembrane do- 
mains thought to be critical for substrate transport. In 
particular, there is absolute conservation of aspartic acid 
residues in the assigned transmembrane regions 1, 6, 10 
and 11 which may be involved in binding of the cationic 
amines transported in cholinergic and aromatic aminer- 
gic secretory vesicles [24]. The vesicular transporters rep- 
resent a distinct class of proteins found in membrane- 
bounded organelles that sustain proton gradients, and 
differ from the family of the neurotransmitter trans- 
porters that are found on plasma membranes (for review, 
see [34]). 
Expression of the Torpedo protein in mammalian fi- 
broblasts confers high-affinity vesamicol binding to 
membranes isolated from transfected cells similar to that 
described on synaptic vesicles (7-20 nM( [19,35]. While 
the binding of vesamicol to synaptic vesicles from C. 
eleguns has never been reported, UNC- 17 expressed sep- 
arately in the same heterologous system demonstrated 
specific vesamicol binding as well, with lower affinity 
(- 124 n&I) than that of Torpedo. It is tempting 
to speculate that amino acid substitutions at crucial 
points of the vesamicol binding site might explain the 
differences in binding affinity between the two species. 
The mechanism of vesamicol inhibition of vesicular 
acetylcholine transport in vitro is not yet clearly under- 
stood. The inhibition constant of the transport of ace- 
tylcholine is similar to the dissociation constant of the 
drug, suggesting that binding and inhibition are directly 
related. However, inhibition is of the mixed non-compe- 
tetive type [19,36] indicating that vesamicol does not 
bind to the a~etylcholine uptake site. Two models to 
account for this data have been proposed by Parsons and 
co-workers [37]: (i) vesamicol binds to an allosteric site 
on the vesicular acetylcholine transporter or (ii) vesami- 
co1 binds to a different protein that acts by an unknown 
mechanism to inhibit acetylcholine uptake. The present 
work is the first direct demonstration that the vesamicol 
binding protein belongs to the family of the vesicular 
neurotransmitter transporters. 
We conclude on the basis of these observations that 
the Torpedo cDNAs described here and unc-17 gene en- 
code the vesicular acetylcholine transporter~i~-affinity 
vesamicol binding protein. Protein expression within a 
membrane fraction in a heterologous cell system with 
preservation of high-affinity vesamicol binding suggests 
that unequivocal demonstration of the role this molecule 
in acetylcholine transport via a proton electrochemical 
gradient in this system should ~timately be possible. 
This will provide a means of establishing the cellular 
basis for vesicular accumulation of the highly evolution- 
arily conserved neurotransmitter acetylcholine. 
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